Watch the video and download the slides

Paul M. Barr MD is a Professor of Medicine at the University of Rochester Medical Center in Rochester, New York. He received his MD from Northeastern Ohio Medical University. His internal medicine and hematology / oncology training was completed at Case Western Reserve University where he also served as Chief Medical Resident. Joining the University of Rochester lymphoma program in 2010, his primary research focus is on novel drug development for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Current efforts revolve around the development of novel combinations incorporating inhibitors targeting the B cell receptor signaling pathway, supported by the Lymphoma Research Foundation and Hope Foundation. Beyond his individual research interests, he is a strong advocate for oncology clinical research. He serves as the Medical Director of the Clinical Trials Office for the Wilmot Cancer Center overseeing all industry sponsored, cooperative group and investigator initiated studies.

Prof. Paul M Barr has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Abbvie, Celgene, Genentech, Merck, Seattle Genetics and TG Theraputics. 

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
LYMPHOMA & MYELOMA CONNECT

LYMPHOMA & MYELOMA CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer and from Karyopharm Therapeutics.

Meet the experts

Other programmes of interest

conference-update Conference update

Episode

6

of 6

episode
Oncology Hemato-oncology 
Listen to Expert Insights on Late-Breaking Data from ASCO 2023

Episode 6: Lymphoma Update: SWOG S1826 trial

Experts
Dr Mansoor Raza Mirza, Dr Paolo Tarantino, Prof. Alexey V Danilov, Prof. Mark Socinski, Prof. Evan Yu, Prof. Thomas Powles, Assoc. Prof. Gerald Prager
  • clock 2 MIN
  • calendar Jun 2023

Oncology Hemato-oncology 
Update From ASH 2022

Highlights from the ASH Annual Meeting

Experts
Dr Matthew J. Matasar
  • clock 4 MIN
  • calendar Dec 2022

Educational programme supported by an independent medical education grant from COR2ED.
Hemato-oncology 
Update from ASCO 2022 – Myeloma

Dr Hans Lee summarises the highlights from the phase 3 DETERMINATION trial: Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM)

Experts
Asst. Prof. Hans Lee
  • clock 2 MIN
  • calendar May 2022

podcast Podcast

Episode

3

of 3

episode
Hemato-oncology 
Choosing the Best Treatment Regimen in Patients with High-Risk Cytogenetics

Episode 3: Choosing the Best Treatment Regimen in Patients with High-Risk Cytogenetics

Experts
Assoc. Prof. María Victoria Mateos, Dr Alexander M Lesokhin
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Mar 2022

Educational programme supported by an independent medical education grant from Karyopharm
Hemato-oncology 
Lymphoma Update from ASH 2021

Dr. Matthew J. Matasar summarises the highlights in lymphoma from ASH 2021, including POLARIX, CAR-T in LBCL and mosunetuzumab in FL

Experts
Dr Matthew J. Matasar
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Dec 2021

Educational programme supported by an independent medical education grant from Bayer
Hemato-oncology 
DLBCL Review Paper Published in The Oncologist

Authored by LYMPHOMA & MYELOMA CONNECT members, the paper ‘Translating the Biology of Diffuse Large B-cell Lymphoma into Treatment’ provides an overview of recent advances in DLBCL biology and how they can be translated into clinical care.

Experts
Dr Matthew J. Matasar, Dr Massimo Magagnoli, Prof. Alexey V Danilov
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Nov 2021

Educational programme supported by an independent medical education grant from Bayer